An independent two-stage DCF analysis by a frontier AI model.
Biogen is in the midst of a difficult, multi-year transition. It is attempting to pivot away from its highly profitable, but eroding, legacy multiple sclerosis franchise toward new, higher-risk neurological frontiers like Alzheimer's and rare diseases. The market has heavily discounted the stock due to clinical missteps and initial commercial stumbles with its recent approvals.
However, at current valuation levels, the market appears to be pricing in a worst-case scenario where the pipeline completely fails to offset legacy declines. The company remains highly profitable, generating over $1 billion in net income annually. If management can execute on its cost-cutting initiatives and achieve even modest commercial success with its newer products, the current share price offers a reasonable margin of safety for patient investors willing to weather near-term volatility.
A highly conservative 4% FCF growth rate is modeled. While legacy MS revenues (Tecfidera) are declining due to generic competition, the company still generates robust current cash flows. This modest growth assumes successful commercial traction of its newer assets to eventually stabilize and slightly grow the top line over the next five years.
A 9% discount rate is appropriate given the elevated risk profile of the business currently. The heavy reliance on successful clinical outcomes and the ongoing commercialization challenges in the controversial Alzheimer's space demand a higher risk premium.
A 2% terminal growth rate aligns with long-term macroeconomic inflation expectations, assuming Biogen stabilizes into a mature biopharma player as its current pipeline matures.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 1.0% | $261.92 | $224.50 | $196.44 | $174.61 | $157.15 |
| 1.5% | $285.73 | $241.77 | $209.53 | $184.88 | $165.42 |
| 2.0% | $314.30 | $261.92 | $224.50 | $196.44 | $174.61 |
| 2.5% | $349.22 | $285.73 | $241.77 | $209.53 | $184.88 |
| 3.0% | $392.88 | $314.30 | $261.92 | $224.50 | $196.44 |
■ Undervalued vs current price ■ Overvalued vs current price
This conservative estimate assumes that the launch of new therapies in Alzheimer's and rare diseases will eventually outpace the ongoing generic erosion of its legacy multiple sclerosis franchise over a 5-year horizon.
Biogen carries higher risk than diversified pharma peers. It is highly concentrated in neurology, a field with historically low clinical success rates, and faces significant near-term revenue transitions.
While it carries risks, its substantial existing cash flow from its legacy business provides a strong floor. The 'undervalued' verdict suggests the market has overly penalized the stock for recent pipeline stumbles.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.